Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024

So-Lun Lee,Mike Y. W. Kwan,Caitriona Murphy,Eunice L. Y. Chan,Joshua S. C. Wong,Sheena G. Sullivan,Malik Peiris,Benjamin J. Cowling

DOI: https://doi.org/10.1101/2024.08.30.24312831

2024-08-30

Abstract:We conducted a test negative study from November 2023 to June 2024, enrolling 4,367 children hospitalized with acute respiratory illness in Hong Kong. Among the children who tested negative for influenza virus and SARS-CoV-2, 56.8% had received influenza vaccination. Between November 2023 and March 2024, influenza A(H3N2) predominated and the VE against influenza A(H3N2) was estimated as 55% (95% CI: 29.6%, 71.8%). VE point estimates were higher for younger children than older children. In February to June 2024 influenza A(H1N1) predominated and VE against influenza A(H1N1) was 54% (95% CI: 33%, 69%) during this period. Influenza B circulated at low intensity throughout the 2023/24 season and VE against influenza B was 66% (95% CI: 42%, 80%). Since its introduction in 2018/19 the school-based influenza vaccination program has substantially increased vaccine uptake in children in Hong Kong and prevented influenza-associated hospitalizations.

What problem does this paper attempt to address?

This paper aims to evaluate the effectiveness of the 2023/24 influenza vaccine among children in Hong Kong, especially for influenza - related hospitalizations. Through the test - negative design, the study investigated children hospitalized for acute respiratory diseases in two hospitals in Hong Kong from November 2023 to June 2024. The study mainly focused on the following points:

1. **Influenza A (H3N2)**: From November 2023 to March 2024, influenza A (H3N2) was the predominant circulating strain. The study estimated that the influenza vaccine was 55% effective (95% confidence interval: 30.6%, 71.8%) in preventing hospitalizations caused by influenza A (H3N2).

2. **Influenza A (H1N1)**: From February to June 2024, influenza A (H1N1) became the predominant circulating strain. The study estimated that the influenza vaccine was 54% effective (95% confidence interval: 33%, 69%) in preventing hospitalizations caused by influenza A (H1N1).

3. **Influenza B**: During the entire study period, the prevalence of influenza B was relatively low. The study estimated that the influenza vaccine was 66% effective (95% confidence interval: 42%, 80%) in preventing hospitalizations caused by influenza B.

In addition, the study also discussed the impact of the school - based influenza vaccination program on increasing children's vaccine coverage since the 2018/19 season, as well as its positive role in reducing influenza - related hospitalizations.

### Main Conclusions
- The influenza vaccine was significantly effective in preventing influenza - related hospitalizations among children in the 2023/24 season.
- The school - based influenza vaccination program significantly increased the vaccination rate among children, thereby reducing the influenza - related hospitalization burden.

### Methods
- **Study Design**: A test - negative design was used to recruit children hospitalized for acute respiratory diseases.
- **Statistical Analysis**: A conditional logistic regression model was used to estimate the vaccine effectiveness, adjusting for factors such as age, gender, previous vaccination history, and underlying medical conditions.

### Limitations
- The sample size was relatively small, especially in the age - stratified analysis, resulting in lower estimation precision.
- The use of rapid antigen tests may affect the hospitalization rate and introduce selection bias.

Overall, this study provides important data support for evaluating the effectiveness of influenza vaccines in children and emphasizes the importance of school - based vaccination programs.